Pfizer Inc. (NYSE:PFE) Position Reduced by Brave Asset Management Inc.

Brave Asset Management Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 15.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,195 shares of the biopharmaceutical company’s stock after selling 5,870 shares during the quarter. Brave Asset Management Inc.’s holdings in Pfizer were worth $927,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in Pfizer in the fourth quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.1 %

PFE stock traded down $0.03 during trading hours on Thursday, hitting $27.75. The company’s stock had a trading volume of 39,620,254 shares, compared to its average volume of 43,835,094. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $157.14 billion, a PE ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22. The stock has a 50 day moving average price of $27.46 and a two-hundred day moving average price of $29.46.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. UBS Group dropped their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Barclays decreased their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.